Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Obrixtamig by Boehringer Ingelheim International for Neuroendocrine Carcinoma: Likelihood of Approval
Obrixtamig is under clinical development by Boehringer Ingelheim International and currently in Phase II for Neuroendocrine Carcinoma. According to GlobalData,...
Data Insights
Obrixtamig by Boehringer Ingelheim International for Small-Cell Lung Cancer: Likelihood of Approval
Obrixtamig is under clinical development by Boehringer Ingelheim International and currently in Phase I for Small-Cell Lung Cancer. According to...